MIT Libraries logoDSpace@MIT

MIT
View Item 
  • DSpace@MIT Home
  • MIT Open Access Articles
  • MIT Open Access Articles
  • View Item
  • DSpace@MIT Home
  • MIT Open Access Articles
  • MIT Open Access Articles
  • View Item
JavaScript is disabled for your browser. Some features of this site may not work without it.

Economics of Beta-Cell Replacement Therapy

Author(s)
Bandeiras, Cátia; Hwa, Albert J.; Cabral, Joaquim M. S.; Ferreira, Frederico Castelo; Finkelstein, Stan Neil; Gabbay, Robert A.; ... Show more Show less
Thumbnail
Download11892_2019_1203_ReferencePDF.pdf (856.6Kb)
Publisher Policy

Publisher Policy

Article is made available in accordance with the publisher's policy and may be subject to US copyright law. Please refer to the publisher's site for terms of use.

Terms of use
Article is made available in accordance with the publisher's policy and may be subject to US copyright law. Please refer to the publisher's site for terms of use.
Metadata
Show full item record
Abstract
Purpose of Review: Type 1 diabetes impacts 1.3 million people in the USA with a total direct lifetime medical cost of $133.7 billion. Management requires a mix of daily exogenous insulin administration and frequent glucose monitoring. Decision-making by the individual can be burdensome. Recent Findings: Beta-cell replacement, which involves devices protecting cells from autoimmunity and allo-rejection, aims at restoring physiological glucose regulation and improving clinical outcomes in patients. Given the significant burden of T1D in the healthcare systems, cost-effectiveness analyses can drive innovation and policymaking in the area. Summary: This review presents the health economics analyses performed for donor-derived islet transplantation and the possible outcomes of stem cell-derived beta cells. Long-term cost-effectiveness of islet transplantation depends on the engraftment of these transplants, and the expenses and thresholds assumed by healthcare systems in different countries. Early health technology assessment analyses for stem cell-derived beta-cell replacement suggest manufacturing optimization is necessary to reduce upfront costs.
Date issued
2019-08
URI
https://hdl.handle.net/1721.1/128519
Department
Massachusetts Institute of Technology. Institute for Data, Systems, and Society
Journal
Current Diabetes Reports
Publisher
Springer Science and Business Media LLC
Citation
Bandeiras, Cátia et al. "Economics of Beta-Cell Replacement Therapy." Current Diabetes Reports 19, 9 (August 2019): 75 © 2019 Springer Science Business Media, LLC
Version: Author's final manuscript
ISSN
1534-4827
1539-0829

Collections
  • MIT Open Access Articles

Browse

All of DSpaceCommunities & CollectionsBy Issue DateAuthorsTitlesSubjectsThis CollectionBy Issue DateAuthorsTitlesSubjects

My Account

Login

Statistics

OA StatisticsStatistics by CountryStatistics by Department
MIT Libraries
PrivacyPermissionsAccessibilityContact us
MIT
Content created by the MIT Libraries, CC BY-NC unless otherwise noted. Notify us about copyright concerns.